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Interest in sound waves dates back to Aristotle’s the-ory of their propagation via air particles.21 Vitruvius proved the hypothesis in the 1st century bc by deter-
mining the mechanism of transmission of sound waves.36 
Ultrasonic waves are sound waves that propagate through 
matter, and their frequencies are above the hearing range 
of human ears (> 20,000 Hz). Medical use of ultrasonic 
imaging started in early 20th century after Paul Langevin 
used it for submarine detection during World War I.6,83 
The use of ultrasound transducers for therapeutic purposes 
started in 193862 and was later applied to the management 
of inflammatory muscle disorders and rheumatoid arthri-
tis.34,35
In the modern era of minimal invasiveness, high-inten-
sity focused ultrasound (HIFU) promises therapeutic util-
ity for multiple neurosurgical pathologies. In the current 
review, we intend to shed light on the use of HIFU in dif-
ferent neurosurgical avenues as well as on its mechanism 
of action. We also provide an update on the outcomes of 
various trials and discuss advances expected from various 
preclinical studies in the future.
Historical Remarks on HIFU
The use of focused ultrasound (FUS) waves for in-
tracerebral ablation was first described by Lynn et al. in 
1942.54 Later, the Fry brothers designed a complex device 
with 4 piezoelectric transducers that had the ability to fo-
cus pinpoint lesions29 and used HIFU for safe ablation of 
intracranial tumors by performing craniectomy to create 
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Since Lynn and colleagues first described the use of focused ultrasound (FUS) waves for intracranial ablation in 1942, 
many strides have been made toward the treatment of several brain pathologies using this novel technology. In the mod-
ern era of minimal invasiveness, high-intensity focused ultrasound (HIFU) promises therapeutic utility for multiple neuro-
surgical applications, including treatment of tumors, stroke, epilepsy, and functional disorders. Although the use of HIFU 
as a potential therapeutic modality in the brain has been under study for several decades, relatively few neuroscientists, 
neurologists, or even neurosurgeons are familiar with it. In this extensive review, the authors intend to shed light on the 
current use of HIFU in different neurosurgical avenues and its mechanism of action, as well as provide an update on the 
outcome of various trials and advances expected from various preclinical studies in the near future. Although the initial 
technical challenges have been overcome and the technology has been improved, only very few clinical trials have thus 
far been carried out. The number of clinical trials related to neurological disorders is expected to increase in the coming 
years, as this novel therapeutic device appears to have a substantial expansive potential. There is great opportunity to 
expand the use of HIFU across various medical and surgical disciplines for the treatment of different pathologies. As this 
technology gains recognition, it will open the door for further research opportunities and innovation.
https://thejns.org/doi/abs/10.3171/2017.11.FOCUS17610
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a window for the transmission of acoustic waves.39 After-
ward, HIFU devices were used in many clinical trials for 
treating tumors of the prostate gland, kidney, and blad-
der.27,33,82
Originally, HIFU was guided by diagnostic ultrasound 
imaging, which has limited guidance accuracy and lacks 
the capacity to determine the real-time temperature.82,84 
With intraoperative MRI, the magnetic resonance–guided 
focused ultrasound (MRgFUS) is more precise than ul-
trasound or a surgeon’s direct visualization. The presoni-
cation volume target is identified by MRI, postsonication 
temperature is measured by proton resonance frequency 
shift by means of fast gradient-echo sequences, and the 
ablated volume is identified by means of T2-weighted fast 
spin-echo sequences.41 
Table 1 summarizes important events in the timeline of 
the development of HIFU technology and current studies 
validating its use for various brain pathologies. 
Principles and Mechanisms of Action of HIFU
In the MRgFUS procedure, a small target is heated 
with ultrasound rays, a technique called sonication. The 
area of tissue exposed to the temperature and the length 
of exposure to this heat define an equivalent thermal dose, 
which determines the extent of the thermal lesion.
In HIFU treatment, FUS is applied for local ablation 
therapy of various types of tumors in the body using an 
intensity (ISATA) of 100–10,000 W/cm2. The primary goal of this technique is to maximize energy accumulation at 
the target area to induce significant biological reactions 
(coagulation necrosis) without instigating harm to sur-
rounding tissues.53
For transcranial treatment, a focused piezoelectric 
transducer is used to converge ultrasonic energy (usually 
1–3 MHz for noninvasive applications) into a target tissue 
and produce localized tissue destruction (Fig. 1). The “fo-
cal zone” can be defined as the area where the ultrasound 
intensity (energy/unit area) is high enough to create a le-
sion. These lesions are ellipsoidal, 8–15 mm in length, and 
have a diameter of 1–2 mm (Fig. 1B).
Thermal Mechanisms of Action
HIFU exposure can be either constant (thermal) or 
pulsed (acoustic cavitation). Ultrasound produces fric-
tional heat by causing vibration of molecules in tissue; a 
temperature of > 56°C maintained for 2 seconds or more 
leads to coagulative necrosis.13,14,75
The thermal damage leads to unplanned cell death. 
The targeted cells retain their outline, their proteins co-
agulate, and their metabolic activity halts.74 In soft tissues, 
HIFU lesions demonstrate a necrotic center and a rim of 
functionally impaired glycogen-poor cells, which eventu-
ally fade, leaving a sharp edge between the affected and 
unaffected tissues 48 hours postexposure, described as an 
“island and moat” presentation.78 An intense acute inflam-
matory response ensues, with the cells detaching from 
their basement membrane and from each other. This is 
followed by chronic inflammation and remodeling, which 
involves cellular regeneration, proliferation, migration, fi-
broblast infiltration, and removal of debris, lasting up to 
3 months.10,77 Later these lesions become encapsulated by 
granulation tissue, finally leading to scar formation.78
Nonthermal (Mechanical) Mechanisms of Action
The pulsed method of HIFU exposure can cause fast 
changes in the targeted tissue pressure, known as the peak 
rarefaction pressure amplitude (PRPA). There is a thresh-
old for PRPA for each tissue at which acoustic cavitation 
(formation of gas- or liquid-filled cavities) occurs, gener-
ally at points of “weakness,” such as the interfaces be-
tween different layers of tissue or fluid-filled structures.28 
The cavitation occurs when the negative component of 
the acoustic waves causes liquid components to fail un-
TABLE 1. Timeline of the development of HIFU technology from 
the late 19th century to the present
Year Description
1880 Piezoelectric effect (Curie)
1907 Electronic vacuum tube (de Forest)
1918 Sonar (Langevin)
1927 Effects on biologic tissues (Looms and Wood)
1942 HIFU effects in animals (Lynn and Putnam; Lynn et al.54)
1950–1969 Molecular studies on HIFU effects (Francis and William 
Fry; Fry and Meyers29)
1951–1960 Radiofrequency generator and electrode development 
(Bernard Cosman, in light of FUS developments)
1951–1967 Radiosurgery and Gamma Knife development (Lars 
Leksell after ultrasound investigation)





Early 1990s Ultrasound phased arrays (Hynyen)
Mid-1990s MR thermometry (Jolesz)
2001 The first integrated MRgFUS machine (InSightec Ltd.)
2006 Report on MRgFUS for treatment of GBM after crani-
otomy (Ram et al.69)
2009 tcMRgHIFU for chronic neuropathic pain (Martin et al.56)
2009 In vitro study for thrombolysis by histotripsy using HIFU 
(Maxwell et al.57)
2010 Phase I clinical trial for noninvasive tumor ablation; to 
prevent heating of the skull, a water cooling, circulat-
ing, and degassing was used (McDannold et al.58)
2011–2013 Use of tcMRgHIFU for ET (Elias et al.22 and Lipsman et 
al.53)
2013–2014 In vitro and in vivo studies for sonothrombolysis of ICH 
(Monteith et al.64 and Harnof et al.38)
2014 Report on the first experience with tcMRgHIFU for PD 
(Magara et al.55)
2016 Randomized controlled trial of tcMRgFUS thalamotomy 
for ET (Elias et al.23)
2016 Preliminary report on randomized controlled trial of 
MRgFUS thalamotomy for PD (Bond et al.)4
ICH = intracerebral hemorrhage.
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der tension, consequently forming gas- and vapor-filled 
“cavities.”44 These acoustic cavitation bubbles oscillate at 
large displacement amplitudes and exert shear stresses on 
the surrounding tissue, causing mechanical tearing. The 
bubbles expand rapidly and collapse, disrupting the cell 
membrane and destroying the surrounding tissue structure 
by a process known as histotripsy.10
The cavitation damage caused by pulsed exposure is 
more random than thermally mediated cell death, as cavi-
tation requires the existence of a nucleation site.44
Initial Challenges With Transcranial MRgHIFU
Bone has a relatively high attenuation coefficient and 
absorbs and reflects considerable amounts of ultrasound 
energy. Its acoustic impedance is much higher than that of 
the soft tissues. This causes an inferior efficacy of energy 
transfer and unwanted heating of the skull in transcranial 
HIFU therapy. To overcome this low-efficiency problem, 
transducers with a large number of high-energy sources 
are employed. An external cooling system that circulates 
chilled water around the scalp helps avoid thermal injury 
to the scalp. To distribute the heat as widely as possible, 
the active area has been maximized through a hemispher-
ic design, known as a piezoelectric component arrange-
ment.
Another challenge in transcranial HIFU was the severe 
aberration of FUS waves. Irregularity in skull thickness 
and a high speed of sound waves in the bone result in the 
defocusing of ultrasound beams.11,42 A computerized mul-
tichannel hemispheric phased-array transducer (ExAblate 
Neuro, InSightec Ltd.) is now being used to overcome this 
problem. The direction of each beam from the transducer 
is controlled by computer calculations and adjusted over 
different skull thicknesses with the help of CT. Combined 
with acoustic simulations, this allows for phase adjust-
ments to focus on a small sharply margined area.43
Current Applications in Neurosurgery
Magnetic resonance–guided high-intensity focused ul-
trasound (MRgHIFU) is rapidly gaining clinical recogni-
tion as a treatment modality that allows noninvasive tissue 
heating and ablation. The setup consists of a positioning 
system, a transducer, and a stereotactic head frame, which 
is placed for patient immobilization during the procedure 
(Fig. 2). A silicone diaphragm is fitted to the scalp, and the 
transducer is filled with degassed water (dissolved oxy-
gen below 1.2 ppm). The cooled degassed water (between 
15°C and 20°C) is circulated between sonications to pre-
vent unwarranted heating and lower the skull temperature.
Tumor Thermocoagulation
Successful transmission of ultrasound waves for 
thermocoagulation of intracranial lesions has been de-
scribed.29,30,39,46,47 Glioblastoma multiforme (GBM) is the 
most common and most aggressive of malignant pri-
mary CNS tumors37 and has been the center of attention 
for multiple HIFU trials. In an article published in 2006, 
Ram et al.69 reported on 3 patients with GBM who un-
derwent MRgHIFU thermal ablation. The shortcomings 
that they faced included the need for craniectomy, per-
formed 7–10 days before sonication, to get a bone window 
for the HIFU transmission, and one of the patients had 
an adverse outcome. The adverse outcome was caused by 
thermal ablation of brain parenchyma outside the target 
in the pathway of transmission of the ultrasound waves, 
leading to neurological deficits. The primary lesions re-
sponded to the MRgHIFU with immediate changes in the 
FIG. 1. A: Noninvasive setup of HIFU transducer with transducer tracker, head-motion tracker, and degassed water. B: HIFU 
transducer converging noninvasive transcranial ultrasonic energy at the ellipsoidal focal zone to produce tissue lesions at depth.
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contrast enhancement in T1-, T2-, and diffusion-weighted 
MRI scans, in addition to thermocoagulation on histo-
logical examination.69 In 2006, Park et al.68 also reported 
the successful ablation of an anaplastic astrocytoma in a 
17-year-old female patient, in whom no other therapeutic 
option was available. A decrease in the tumor volume and 
surrounding edema was noted on the 6-month follow-up 
imaging. In 2010, McDannold et al. reported on a Phase I 
clinical trial conducted at Brigham and Women’s Hospital 
in 3 GBM patients; the tumors were treated with transcra-
nial MRgHIFU (tcMRgHIFU) using the ExAblate 3000 
(InSightec) treatment system.58 The authors described the 
use of transcranial HIFU and real-time temperature mea-
surement of target tissue with MR. This trial was limited 
by the low power of the HIFU device (650–800 W), which 
was unable to thermally ablate the focused lesion,58 and 
was stopped when a fourth patient suffered a cavitation-
induced intracranial hemorrhage and subsequently died.
In 2014, Coluccia et al.16 reported a case from an ongo-
ing Phase I trial in which a 63-year-old patient was treated 
with tcMRgHIFU for a centrally located recurrent GBM. 
FUS pulses of 10–25 seconds’ duration with an acoustic 
power of 150–950 W were transmitted to the targeted tu-
mor. The treatment consisted of 25 sonications, and the 
energy was increased until it reached 19,950 J per sonica-
tion; the intraoperative MR thermometry identified 17 of 
the 25 sonications as capable of coagulation, with temper-
ature peaks in the range of 55°C–65°C. Immediate post-
procedural diffusion-weighted MRI identified multiple 
bright lesions in the targeted tumor volume. MRI at 21 
days’ follow-up demonstrated tumor ablation with no tu-
mor progression. Long-term postprocedural examination 
showed improvement in neurological deficits.16
Ultrasound contrast agents, such as preformed mi-
crobubbles, amplify focal heating during sonication and 
have been used to reduce the time-averaged power needed 
during transcranial FUS ablation.79 In a study on rabbits, 
McDannold et al.60 demonstrated that the administration 
of a microbubble-based ultrasound contrast agent reduced 
the acoustic power needed to induce lesions to less than 
one-tenth of what is required to produce thermal lesions 
without the contrast agents.
Based on these studies, transcranial MRgFUS 
(tcMRgFUS) seems to be a feasible treatment option for 
tumor ablation; however, further investigations are neces-
sary. According to Medel et al.,61 high-grade gliomas are 
not an ideal pathology for HIFU, and the technique might 
be more effective for well-circumscribed lesions, such 
as metastases or benign tumors, inaccessible to surgery. 
Present trials underway in the United States and Switzer-
land in patients with metastases and gliomas are expected 
to provide further data regarding treatment efficiency.
Functional Neurosurgery
Transcranial MRgHIFU now gives interventionists the 
capability to treat various chronic and therapeutically re-
sistant brain diseases with precise ablation of the focused 
targets in the thalamus, subthalamus, or basal ganglia.2 
These locations are centers to many pathological condi-
tions, namely neuropathic pain, Parkinson’s disease (PD), 
and essential tremor (ET).
Chronic Neuropathic Pain
In 2009, Martin et al.56 reported the first successful 
application of tcMRgHIFU for functional neurosurgery. 
They treated 9 patients with chronic neuropathic pain with 
FIG. 2. Schematic of tcMRgHIFU setup.
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medial thalamotomies. The ablations were precisely locat-
ed within a diameter of 4 mm according to MRI. There 
were no neurological deficits on follow-up.56
In 2012, Jeanmonod et al.45 also reported the use of 
tcMRgHIFU to perform noninvasive central lateral thala-
motomies in 11 patients for chronic therapy-resistant neu-
ropathic pain. They used a hemispheric 1024-element 
phased-array transducer functioning at 650 kHz to yield 
precise lesioning of the central lateral nucleus of the thal-
amus. Pain relief 48 hours postprocedure averaged 68% 
(range 30%–100%). One patient had a bleed at the target 
with ischemia in the motor thalamus. Two safety mea-
sures were introduced—detection of potential cavitation 
by a cavitation detector and the maintenance of sonication 
temperatures below 60°C.
Essential Tremor
In 2013, Elias et al.22 reported on 15 patients treated 
with tcMRgHIFU ablation of the unilateral ventral inter-
mediate nucleus (VIM) of the thalamus for therapeutically 
resistant ET from February 2011 to December 2011 in an 
open-label, uncontrolled study. At 12 months’ follow-up, 
significant improvement was noticed in hand tremors (p = 
0.001), total tremor scores (p = 0.001), disability scores (p 
= 0.001), and quality of life scores (p = 0.001) in compari-
son with the preoperative scores. Adverse effects included 
transient sensory, motor, speech, and cerebellar abnormal-
ities, with 4 patients developing permanent paresthesias. 
Lipsman et al.53 treated 4 patients complaining of chronic 
ET resistant to medical therapy with tcMRgHIFU. These 
patients underwent precise ablation of the thalamic focus 
of the ET, with a mean reduction in tremor scores of 81.3% 
at 3 months compared with baseline. Gallay et al. also re-
ported favorable results for tcMRgFUS cerebellothalamic 
tractotomy in 21 patients with ET.31
In 2016, Elias et al.23 reported on their randomized 
controlled trial of tcMRgFUS thalamotomy versus a sham 
procedure. Hand-tremor scores improved in tcMRgFUS 
thalamotomy patients (from 18.1 points at baseline to 9.6 
at 3 months), with a between-group difference in the mean 
change of 8.3 points (95% CI 5.9–10.7, p < 0.001).23
Parkinson’s Disease
Parkinson’s disease (PD), a degenerative disorder of 
the CNS involving basal ganglia presenting with both mo-
tor and neuropsychiatric symptoms,49 has been a focus of 
HIFU research for the last few years. In 2014, Magara et 
al.55 were the first to report on the use of MRgHIFU for 
the treatment of PD, describing the results of pallidotha-
lamic tractotomy in 13 patients. For assessment purposes, 
the Unified Parkinson’s Disease Rating Scale (UPDRS) 
and global symptom relief (GSR) were used at follow-up. 
Thermal ablation was repeated up to 5 times to achieve a 
higher volume of thermally ablated lesions causing vis-
ible ablated lesions on T2-weighted images. These patients 
achieved clinical reduction in UPDRS (60.9%) and GSR 
(56.7%).55
In 2015, Schlesinger et al. reported on the treatment of 
moderate to severe tremor in PD in 7 patients with VIM 
thalamotomy using MRgHIFU.72 The same team reported 
additional experience in 30 patients with PD and ET in 
February 2017.72 This study included 18 patients with ET, 
9 with PD, and 3 with ET-PD who underwent MRgFUS 
VIM thalamotomy to relieve medication-resistant tremor. 
Adverse events experienced postprocedure in some pa-
tients included gait ataxia, unsteady feeling, taste distur-
bances, asthenia, and hand ataxia. None of these compli-
cations lasted beyond 3 months.
Bond et al.4 have reported early results of their dou-
ble-blind, randomized controlled trial on the effective-
ness of MRgFUS thalamotomy in tremor-dominant PD. 
They found that MRgFUS treatment was associated with 
improvement in hand tremor and a clinically significant 
reduction in mean UPDRS scores postprocedure, but the 
final results of this study are still awaited.
Na et al.66 reported the only case of pallidotomy, le-
sioning of the globus pallidus interna, using MRgFUS in 
a woman with severe levodopa-related motor complica-
tions. There are technical issues in focusing ultrasound 
rays to find the exact target within the pallidum. Another 
challenge is the proximity of the optic nerve to the globus 
pallidus internus. It is not clear what will be the best tar-
get for treating PD symptoms or whether different targets 
should be used for different patients. Another question is 
the safety of the bilateral procedure.
As of this writing, MRgFUS is approved for the treat-
ment of medication-refractory PD symptoms in Israel, Eu-
rope, Korea, and Russia.73
Obsessive-Compulsive Disorder and Depression
Jung et al., with their 2015 publication,48 were the first 
to describe the use of MRgFUS for the treatment of medi-
cally refractory obsessive-compulsive disorder (OCD). 
They performed bilateral thermal anterior limb capsu-
lotomy in 4 patients and reported favorable results. Simi-
larly, a clinical trial of 10 patients evaluated the feasibility, 
safety, and initial efficacy of MRgFUS in the treatment of 
major depressive disorder.51 Currently, a single arm, non-
randomized trial of MRgFUS targeting the anterior limb 
of the internal capsule for treatment-refractory OCD has 
just begun (NCT03156335; clinicaltrials.gov). The results 
of all these trials are eagerly awaited and could change the 
clinical management of OCD and depression.
Enhancing Drug Delivery Across the Blood-Brain Barrier
Several animal studies have demonstrated the poten-
tial of FUS to deliver chemotherapeutic agents, antibod-
ies, growth factors, or genes to the desired area of the 
brain.52,59,80 By modifying the sonication parameters from 
those used for ablation, a controlled, reversible, and repro-
ducible opening of the blood-brain barrier (BBB) can be 
achieved, allowing for the delivery of targeted drugs, such 
as liposomal doxorubicin; nanoparticles; fluorophores; 
and naked DNA injected systemically to locally sonicated 
tissue in vivo.59
A preclinical study using anti–dopamine-4 (anti-D4) 
antibodies demonstrated a high degree of selectivity for 
the FUS-targeted area.55 Targeting ligands can also be 
conjugated to microbubbles, enabling the microbubble 
complex to accumulate selectively in areas of interest. 
When these microbubbles are destroyed with low-fre-
quency, high-power ultrasound, the microvessel walls 
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become permeable, allowing for the drugs or genes con-
tained within microbubbles to be released into the blood-
stream and then delivered to tissue by convective forces.43 
Preclinical studies involving chemotherapeutic agent 
demonstrated that anti-Her-2 antibody trastuzumab (Her-
ceptin) was successfully delivered into the brain with a 
concentration gradient that matched the expected BBB 
disruption magnitude measured using MRI.3,52 This opens 
the possibility of estimating the actual concentration of a 
drug at the target location using MRI-guided BBB open-
ing.3,52
Several preclinical studies have also demonstrated the 
successful delivery of anti-amyloid antibodies and other 
disease-modifying drugs across the BBB using FUS ther-
apy for the treatment of Alzheimer’s disease (AD).8,12 Re-
cently, a Phase I clinical trial to evaluate the feasibility and 
safety of opening the BBB in AD patients utilizing FUS 
has commenced (NCT02986932; clinicaltrials.gov). It is 
hoped that this trial will be a milestone in the path toward 
successful treatment of AD.
Sonothrombolysis
Ischemic Stroke
As evident from several preclinical studies, HIFU-
based thrombolysis has recently emerged as a promising 
drug-free treatment option for ischemic stroke.9,17,57,67,76,85 
FUS causes microbubble oscillation, leading to mechani-
cal disruption of the ischemic clot and improving rates 
of recanalization.20 Low-intensity ultrasound combined 
with systemic delivery of microbubble contrast agents 
has been shown to improve thrombolysis in the presence 
or absence of tissue plasminogen activator (tPA) in the 
past.7,19,20,24 The Combined Lysis of Thrombus in Brain Is-
chemia Using Transcranial Ultrasound and Systemic tPA 
(CLOTBUST) trial and the Transcranial Low-Frequency 
Ultrasound-Mediated Thrombolysis in Brain Ischemia 
(TRUMBI) trial with unfocused, low-frequency (300 
kHz) ultrasound have shown some promise, but with com-
plications such as increased hemorrhage rates.1,18 HIFU 
as a stand-alone method for thrombolysis seems to be 
more advantageous, as it reduces the risk of hemorrhage 
by eliminating the side effects of thrombolytic drugs as 
well as adequately causing thrombolysis without damage 
to the targeted vessels.9,57,85 Also, HIFU reduces the treat-
ment time from hours to minutes, which may cause sig-
nificant reductions in the size of infarct and lead to better 
clinical outcomes in stroke patients,9,17,57,67,76,85 and there-
fore has the potential to revolutionize current treatment 
paradigms. Further investigations and clinical trials are 
warranted.
Hemorrhagic Stroke
Preclinical studies by Harnof et al.38 and Monteith et 
al.64 demonstrated the feasibility of HIFU for fast, effi-
cient, and safe thrombolysis of intracranial hemorrhage in 
both in vitro and in vivo models without introducing tPA. 
MRgHIFU should provide the ability to lyse an intrace-
rebral thrombus with a high degree of accuracy, followed 
by aspiration in a minimally invasive manner under im-
mediate MRI guidance, without requiring any indwelling 
catheters. Clinical trials are expected to begin soon.
HIFU-Induced Immunomodulation and Antitumor Immunity
The release of tumor antigens from necrotic cells and 
a diverse array of endogenous signals from HIFU-dam-
aged tumor cells can enhance an antitumor immune re-
sponse.40,71 Several clinical studies have provided evidence 
that immunomodulation occurs following HIFU treatment, 
which could affect the patient’s immune status.5,71 Animal 
studies suggest that following a FUS treatment there is a 
rise in CD3+ and CD4+ subsets and the CD4+/CD8+ ra-
tio in the blood due to the activation of dendritic cells.40,87 
HIFU might be an attractive option in situations in which 
a host’s antitumor immunity needs to be enhanced. A 
HIFU-induced strong antitumor immune response could 
help to combat residual tumor cells at the primary lesion 
site and suppress metastasis.40,87
Future Applications of tcMRgFUS
Trigeminal Neuralgia
A recent cadaveric model study with real-time MR 
thermometry and experimentation with thermocouples in 
a transcranial in vitro setup successfully demonstrated the 
capability to produce a focal rise in temperature within 
the trigeminal nerve without heating the bone or causing 
changes in the temperature of the immediate structures.65 
Although more investigation is needed in preclinical mod-
els and, eventually, in patients, this does illustrate the ex-
pansive potential of MRgFUS.
Neuromodulation and Epilepsy
In the past years, several in vitro as well as in vivo stud-
ies have demonstrated the ability of FUS to both reversibly 
and irreversibly block nerve conduction.15,25,26,70,86 Other 
studies have demonstrated activation of neural tissue, both 
peripherally and in the CNS.32,50,81 These effects have been 
postulated to occur as a result of mechanical stimuli (re-
versible) and thermal ablation (potentially irreversible). 
These techniques of modulating neural transmission also 
promise potential application in the treatment of epilepsy. 
In a murine epilepsy model, MRgFUS has been shown to 
decrease epileptic activity that was induced by intraperi-
toneal injection of pentylenetetrazol.63 Although further 
studies are warranted, neuromodulation with MRgFUS 
might provide clinicians with a future potential to nonin-
vasively target a seizure focus in the brain before its per-
manent ablation, if needed.
Conclusions
Several developments have occurred in the field of 
tcMRgFUS, and the modality seems poised to broaden 
the neurosurgical armamentarium. It holds the prom-
ise of providing multiple therapeutic options for various 
neurological diseases. Despite improvements that have 
overcome the initial technical challenges, only very few 
clinical trials have thus far been carried out. The num-
ber of trials related to neurological disorders is expected 
to increase in the coming years, as this novel therapeutic 
device appears to have substantial expansive potential. 
There are abundant opportunities for research on the use 
of this technology across various medical and neurologi-
cal disciplines.
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